Physician profile
Peter J Sargon
NPI 1790941466
$4,009.10
in general payments reported to CMS, 2019-2025
10 companies · $20.36 in 2025
The $20.36 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,072 · 2020: $76.48 · 2021: $141 · 2022: $196 · 2023: $302 · 2024: $200 · 2025: $20.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,200.11 | 2019-2024 | Exalt Model D |
| Ambu INC. | $217.70 | 2020-2021 | |
| Medtronic, INC. | $138.21 | 2023 | Gi Genius |
| Madrigal Pharmaceuticals | $121.48 | 2024 | Rezdiffra |
| Covidien LP | $116.65 | 2019 | |
| Cook Medical LLC | $76.09 | 2019-2023 | Hemospray |
| Creo Medical INC. | $53.33 | 2023 | Speedboat |
| Conmed Corporation | $45.94 | 2023 | Conmed Biliary |
| Ipsen Biopharmaceuticals, INC | $20.36 | 2025 | Bylvay |
| Celgene Corporation | $19.23 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sargon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.